dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | López-Miranda, Elena |
dc.contributor.author | Perez-Garcia, Jose Manuel |
dc.contributor.author | Brain, Etienne |
dc.contributor.author | Ravnik, Maja |
dc.contributor.author | Escriva de Romaní Muñoz, Santiago Ignacio |
dc.contributor.author | Cortés Castan, Javier |
dc.contributor.author | Di Cosimo, Serena |
dc.date.accessioned | 2021-09-01T10:16:22Z |
dc.date.available | 2021-09-01T10:16:22Z |
dc.date.issued | 2020-11-25 |
dc.identifier.citation | López-Miranda E, Pérez-García JM, Di Cosimo S, Brain E, Ravnik M, Escrivá-de-Romaní S, et al. Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial. Cancers. 2020 Nov 25;12(12):3509. |
dc.identifier.issn | 2072-6694 |
dc.identifier.uri | https://hdl.handle.net/11351/6248 |
dc.description | HER2-positiu; Càncer de mama metastàsic; Trastuzumab emtansina |
dc.description.sponsorship | Funding for this research was provided by F. Hoffmann-La Roche Ltd. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Cancers;12(12) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Mama - Càncer |
dc.subject | Medicaments antineoplàstics - Efectes secundaris |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.subject.mesh | /adverse effects |
dc.title | Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/cancers12123509 |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.subject.decs | /efectos adversos |
dc.relation.publishversion | https://www.mdpi.com/2072-6694/12/12/3509 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [López-Miranda E] Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain. Medical Department, Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ, USA. Medical Department, Medica Scientia Innovation Research (MedSIR), Barcelona, Spain. [Pérez-García JM] Medical Department, Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ, USA. Medical Department, Medica Scientia Innovation Research (MedSIR), Barcelona, Spain. International Breast Cancer Center (IBCC), Quiron Group, Medical Oncology Department, Barcelona, Spain. [Di Cosimo S] Medical Department, Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ, USA. Medical Department, Medica Scientia Innovation Research (MedSIR), 08018 Barcelona, Spain. Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. [Brain E] Department of Medical Oncology, Institut Curie, St. Cloud, France. [Ravnik M] Department of Oncology, University Medical Centre Maribor, Maribor, Slovenia. [Escrivá-de-Romaní S] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Cortés J] Medical Department, Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ, USA. Medical Department, Medica Scientia Innovation Research (MedSIR), Barcelona, Spain. International Breast Cancer Center (IBCC), Quiron Group, Medical Oncology Department, Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 33255658 |
dc.identifier.wos | 000601788300001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |